| Summary of segment financial information to assist in segment performance evaluation, resource allocation, and decision-making |
In addition, the CODM is regularly provided the following significant segment financial information to assist in segment performance evaluation, resource allocation, and decision-making (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
For the three months
ended June 30, |
|
|
For the six months
ended June 30, |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Research and Development |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Clinical research and outside services |
|
$ |
4,879 |
|
|
$ |
3,157 |
|
|
$ |
7,988 |
|
|
$ |
7,993 |
|
| Compensation and related |
|
|
774 |
|
|
|
1,117 |
|
|
|
1,648 |
|
|
|
2,305 |
|
Other research and development expenses (a) |
|
|
— |
|
|
|
203 |
|
|
|
— |
|
|
|
203 |
|
| Stock-based compensation expense |
|
|
— |
|
|
|
— |
|
|
|
57 |
|
|
|
13,965 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total research and development expense |
|
$ |
5,653 |
|
|
$ |
4,476 |
|
|
$ |
9,693 |
|
|
|
24,465 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| General and Administrative |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Compensation and related |
|
$ |
589 |
|
|
$ |
613 |
|
|
|
1,328 |
|
|
|
1,509 |
|
| Consulting and professional services |
|
|
645 |
|
|
|
268 |
|
|
|
2,301 |
|
|
|
922 |
|
Other general and administrative expenses (b) |
|
|
471 |
|
|
|
1,029 |
|
|
|
831 |
|
|
|
1,926 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total general and administrative expense |
|
$ |
1,705 |
|
|
$ |
1,909 |
|
|
|
4,460 |
|
|
|
4,357 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| (a) |
Other research and development expenses include depreciation and amortization expense and a non-cash research and development expense for the ordinary shares issuable pursuant to the Hutchmed Agreement of $14.0 million for the six months ended June 30, 2024. |
| (b) |
Other general and administrative expenses include depreciation and amortization expense, and certain departmental expenses. |
|
In addition , the CODM is regularly provided the following significant segment financial information to assist in segment performance evaluation, resource allocation, and decision-making (in thousands):
|
|
|
|
|
|
|
|
|
| |
|
|
|
| |
|
|
|
|
|
|
Research and Development |
|
|
|
|
|
|
|
|
Clinical research and outside services |
|
$ |
12,666 |
|
|
$ |
15,275 |
|
Compensation and related |
|
|
4,001 |
|
|
|
6,113 |
|
Consulting and professional services |
|
|
2 |
|
|
|
— |
|
Other research and development expenses (a) |
|
|
15,440 |
|
|
|
538 |
|
|
|
|
|
|
|
|
|
|
Total research and development expense |
|
$ |
32,109 |
|
|
$ |
21,926 |
|
|
|
|
|
|
|
|
|
|
General and Administrative |
|
|
|
|
|
|
|
|
Compensation and related |
|
$ |
2,645 |
|
|
|
2,602 |
|
Consulting and professional services |
|
|
3,152 |
|
|
|
1,351 |
|
Other general and administrative expenses (b) |
|
|
2,594 |
|
|
|
4,008 |
|
|
|
|
|
|
|
|
|
|
Total general and administrative expense |
|
$ |
8,391 |
|
|
$ |
7,961 |
|
|
|
|
|
|
|
|
|
|
| (a) |
Other research and development expenses include depreciation and amortization expense, losses on sale of property and equipment of $ 1.3 million for the year ended December 31, 2024, non-cash research and development expense for issuance of ordinary shares related to the Hutchmed Agreement of $14.0 million for the year ended December 31, 2024, and certain departmental expenses. |
| (b) |
Other general and administrative expenses include depreciation expense, amortization expense, and certain departmental expenses. |
|
| Summary of segment financial information to assist in segment performance evaluation, resource allocation, and decision-making |
In addition to the significant expense categories included within consolidated net loss presented in the condensed consolidated statements of operations and comprehensive loss, see below for disaggregated amounts that comprise research and development expenses (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Research and development |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Direct research and development expenses by program: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
$ |
313 |
|
|
$ |
3,846 |
|
|
$ |
712 |
|
|
$ |
6,304 |
|
| |
|
|
3,123 |
|
|
|
2,318 |
|
|
|
5,574 |
|
|
|
3,982 |
|
| |
|
|
33 |
|
|
|
86 |
|
|
|
41 |
|
|
|
498 |
|
| Discovery and other programs |
|
|
64 |
|
|
|
802 |
|
|
|
85 |
|
|
|
759 |
|
| Unallocated expense: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Personnel related (including stock-based
compensation) |
|
|
313 |
|
|
|
2,150 |
|
|
|
948 |
|
|
|
5,722 |
|
| Other research and development cost |
|
|
179 |
|
|
|
630 |
|
|
|
380 |
|
|
|
2,212 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total research and development expenses |
|
$ |
4,025 |
|
|
$ |
9,832 |
|
|
$ |
7,740 |
|
|
$ |
19,477 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In addition to the significant expense categories included within consolidated net loss presented in the consolidated statements of operations and comprehensive loss, see below for disaggregated amounts that comprise research and development expenses (in thousands):
|
|
|
|
|
|
|
|
|
| |
|
|
|
| |
|
|
|
|
|
|
Research and development |
|
|
|
|
|
|
|
|
Direct research and development expenses by program: |
|
|
|
|
|
|
|
|
|
|
$ |
8,684 |
|
|
$ |
11,608 |
|
|
|
|
9,682 |
|
|
|
8,068 |
|
|
|
|
480 |
|
|
|
2,677 |
|
Discovery and other programs |
|
|
1,092 |
|
|
|
10,218 |
|
Unallocated expense: |
|
|
|
|
|
|
|
|
Personnel related (including stock-based compensation) |
|
|
8,186 |
|
|
|
19,571 |
|
Other research and development cost |
|
|
2,751 |
|
|
|
7,510 |
|
|
|
|
|
|
|
|
|
|
Total research and development expenses |
|
$ |
30,875 |
|
|
$ |
59,652 |
|
|
|
|
|
|
|
|
|
|
|